Columbia Trust Co 01012016 Acquires 516 Shares of Abbott Laboratories (NYSE:ABT)

Columbia Trust Co 01012016 lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 9.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,730 shares of the healthcare product maker’s stock after acquiring an additional 516 shares during the quarter. Columbia Trust Co 01012016’s holdings in Abbott Laboratories were worth $677,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ABT. Main Street Financial Solutions LLC boosted its position in shares of Abbott Laboratories by 1.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 6,490 shares of the healthcare product maker’s stock valued at $752,000 after purchasing an additional 83 shares in the last quarter. Glassman Wealth Services boosted its position in shares of Abbott Laboratories by 6.2% during the 2nd quarter. Glassman Wealth Services now owns 1,479 shares of the healthcare product maker’s stock valued at $171,000 after purchasing an additional 86 shares in the last quarter. Signature Estate & Investment Advisors LLC boosted its position in shares of Abbott Laboratories by 3.7% during the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 2,438 shares of the healthcare product maker’s stock valued at $288,000 after purchasing an additional 86 shares in the last quarter. 44 Wealth Management LLC boosted its position in shares of Abbott Laboratories by 4.5% during the 2nd quarter. 44 Wealth Management LLC now owns 2,042 shares of the healthcare product maker’s stock valued at $237,000 after purchasing an additional 87 shares in the last quarter. Finally, Intrust Bank NA boosted its position in shares of Abbott Laboratories by 0.4% during the 2nd quarter. Intrust Bank NA now owns 25,447 shares of the healthcare product maker’s stock valued at $2,950,000 after purchasing an additional 89 shares in the last quarter. Institutional investors own 72.46% of the company’s stock.

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 9,500 shares of the stock in a transaction on Thursday, September 2nd. The stock was sold at an average price of $127.50, for a total transaction of $1,211,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Philip P. Boudreau sold 8,000 shares of the stock in a transaction on Monday, October 25th. The shares were sold at an average price of $126.49, for a total value of $1,011,920.00. The disclosure for this sale can be found here. Insiders have sold 182,783 shares of company stock valued at $23,066,012 over the last ninety days. 1.50% of the stock is currently owned by company insiders.

Shares of ABT opened at $125.07 on Thursday. The company has a current ratio of 1.83, a quick ratio of 1.42 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $221.16 billion, a price-to-earnings ratio of 31.03, a PEG ratio of 2.09 and a beta of 0.68. The stock has a 50 day moving average of $123.74 and a 200 day moving average of $120.66. Abbott Laboratories has a 12 month low of $105.32 and a 12 month high of $131.60.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Tuesday, October 19th. The healthcare product maker reported $1.40 EPS for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.46. The company had revenue of $10.93 billion during the quarter, compared to the consensus estimate of $9.56 billion. Abbott Laboratories had a return on equity of 28.39% and a net margin of 17.12%. Abbott Laboratories’s revenue was up 23.4% on a year-over-year basis. During the same period last year, the business posted $0.98 earnings per share. As a group, equities research analysts predict that Abbott Laboratories will post 5.05 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Monday, November 15th. Investors of record on Friday, October 15th were given a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.44%. The ex-dividend date was Thursday, October 14th. Abbott Laboratories’s payout ratio is 44.67%.

Several equities research analysts recently commented on ABT shares. Raymond James upped their target price on Abbott Laboratories from $128.00 to $134.00 and gave the company an “outperform” rating in a research report on Thursday, October 21st. Atlantic Securities raised Abbott Laboratories from a “neutral” rating to an “overweight” rating and set a $144.00 price target on the stock in a research note on Wednesday, October 27th. Cowen reaffirmed a “buy” rating and set a $140.00 price target on shares of Abbott Laboratories in a research note on Friday, October 8th. Citigroup upped their price target on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, October 1st. Finally, Morgan Stanley upped their price target on Abbott Laboratories from $136.00 to $146.00 and gave the stock an “overweight” rating in a research note on Thursday, October 21st. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $134.94.

About Abbott Laboratories

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products.

Featured Article: What are the benefits of investing in REITs?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.